drugset / Trial / NCT03593226
Study to Evaluate Safety & Tolerability of AGI-134 in Solid Tumour
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate if AGI-134 given alone is safe and tolerate in treating patients with unresectable/metastatic solid tumours.
Timeline
- Start
- 2018-11-30
- Primary completion
- 2023-12-31
- Completion
- 2023-12-31
Outcome
Met primary endpoint
release “A first-in-human Phase 1/2a study of AGI-134 met its primary endpoint for safety and tolerability” biolinerx.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AGI-134 | Unknown | 25 mg | Other |
| Subject | AGI-134 | Unknown | 50 mg | Other |
| Subject | AGI-134 | Unknown | 100 mg | Other |
| Subject | AGI-134 | Unknown | 200 mg | Other |
Indications
No indication recorded.